https://orcid.org/0000-0002-6187-2385
Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Tanya M Laidlaw, Andrew Menzies-Gow, Scott Caveney, Joseph K Han, Nicole Martin, Elliot Israel, Jason K Lee, Jean-Pierre Llanos, Neil Martin, Ayman Megally, Bhavini Parikh, Sylvia Vong, Tobias Welte & Jonathan Corren. (2023) Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR. Journal of Asthma and Allergy 16, pages 915-932.
Read now
Read now
Joseph D Spahn, Christopher E Brightling, Paul M O’Byrne, Lisa J Simpson, Nestor A Molfino, Christopher S Ambrose, Neil Martin & Teal S Hallstrand. (2023) Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review. Journal of Asthma and Allergy 16, pages 755-774.
Read now
Read now
Mara Habash, Hannah Guiang, Irvin Mayers, Anna Quinton, Vivian Vuong, Aidan Dineen, Sumeet Singh, Danny Gibson & Adrian P. Turner. (2023) Cost-effectiveness of tezepelumab in Canada for severe asthma. Journal of Medical Economics 26:1, pages 902-914.
Read now
Read now
Maria Gabriella Matera, Josuel Ora, Luigino Calzetta, Paola Rogliani & Mario Cazzola. (2023) Investigational anti IL-13 asthma treatments: a 2023 update. Expert Opinion on Investigational Drugs 32:5, pages 373-386.
Read now
Read now
Masaharu Shinkai, Motohiro Ebisawa, Yasushi Fukushima, Satomi Takeuchi, Hiroshi Okada, Tatsuro Tokiyo, Nobuya Hayashi, Mami Takikawa, Gene Colice & Gun Almqvist. (2023) One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study. Journal of Asthma 60:3, pages 616-624.
Read now
Read now
Jane R Parnes, Nestor A Molfino, Gene Colice, Ubaldo Martin, Jonathan Corren & Andrew Menzies-Gow. (2022) Targeting TSLP in Asthma. Journal of Asthma and Allergy 15, pages 749-765.
Read now
Read now
Andrew Menzies-Gow, Jason Steenkamp, Sumeet Singh, Wilma Erhardt, Jennifer Rowell, Pallavi Rane, Neil Martin, Jean Pierre Llanos & Anna Quinton. (2022) Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. Journal of Medical Economics 25:1, pages 679-690.
Read now
Read now
Agamemnon Bakakos, Nikoletta Rovina, Stelios Loukides & Petros Bakakos. (2022) Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences. Expert Opinion on Biological Therapy 22:7, pages 855-870.
Read now
Read now
Sady Alpizar, Ayman Megally, Claudia Chen, Abhi Raj, John Downie & Gene Colice. (2021) Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma. Journal of Asthma and Allergy 14, pages 381-392.
Read now
Read now
Articles from other publishers (80)
Jeremy Cole, Iwona Cąpała-Szczurko, Stephanie Roseti, Claudia Chen, Scott Caveney, Anastasia A. Aksyuk, Katie Streicher, Sandhia Ponnarambil & Gene Colice. (2023) Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study. Pulmonary Therapy.
Crossref
Crossref
Yahiya Y. Syed. (2023) Tezepelumab in severe asthma: a profile of its use. Drugs & Therapy Perspectives.
Crossref
Crossref
Masaharu Shinkai & Tadataka Yabuta. (2023) Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma. Immunotherapy 15:17, pages 1435-1447.
Crossref
Crossref
Pierre-Alexandre Gagnon, Martin Klein, John De Vos, Sabrina Biardel, Andréanne Côté, Krystelle Godbout, Michel Laviolette, Catherine Laprise, Said Assou & Jamila Chakir. (2023) S100A alarmins and thymic stromal lymphopoietin (TSLP) regulation in severe asthma following bronchial thermoplasty. Respiratory Research 24:1.
Crossref
Crossref
Mandya V. Greeshma, Mohammed Kaleem Ullah, Ulaganathan Mabalirajan, SubbaRao V. Madhunapantula & Padukudru Anand Mahesh. (2023) Molecular mechanisms of steroid-resistant asthma. Exploration of Asthma & Allergy 1:5, pages 174-185.
Crossref
Crossref
Scott M. O’Grady & Hirohito Kita. (2023) ATP functions as a primary alarmin in allergen-induced type 2 immunity. American Journal of Physiology-Cell Physiology 325:5, pages C1369-C1386.
Crossref
Crossref
Phichayut Phinyo, Thanachit Krikeerati, Irin Vichara-Anont & Torpong Thongngarm. (2023) Efficacy and Safety of Biologics for Oral Corticosteroid–Dependent Asthma: A Systematic Review and Network Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice.
Crossref
Crossref
Simone Marcella, Angelica Petraroli, Luisa Canè, Anne Lise Ferrara, Remo Poto, Roberta Parente, Francesco Palestra, Leonardo Cristinziano, Luca Modestino, Maria Rosaria Galdiero, Maria Monti, Gianni Marone, Massimo Triggiani, Gilda Varricchi & Stefania Loffredo. (2023) Thymic stromal lymphopoietin (TSLP) is a substrate for tryptase in patients with mastocytosis. European Journal of Internal Medicine 117, pages 111-118.
Crossref
Crossref
Xiangjing Meng, Sumei Guo, Xiaoxia Zhang, Bo Jiao, Xiaohan Yang, Ming Li, Chao Li, Jin He, Shangya Chen, Cheng Peng, Hua Shao & Qiang Jia. (2023) HMGB1 inhibition reduces TDI-induced occupational asthma through ROS/AMPK/autophagy pathway. Ecotoxicology and Environmental Safety 266, pages 115575.
Crossref
Crossref
Ian D. Pavord, Flavia C.L. Hoyte, Andrew W. Lindsley, Christopher S. Ambrose, Joseph D. Spahn, Stephanie L. Roseti, Bill Cook, Janet M. Griffiths, Åsa Hellqvist, Nicole Martin, Jean-Pierre Llanos, Neil Martin, Gene Colice & Jonathan Corren. (2023) Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR). Annals of Allergy, Asthma & Immunology 131:5, pages 587-597.e3.
Crossref
Crossref
Yoni E. van Dijk, Niels W. Rutjes, Korneliusz Golebski, Havva Şahin, Simone Hashimoto, Anke-Hilse Maitland-van der Zee & Susanne J. H. Vijverberg. (2023) Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab. Pediatric Drugs 25:6, pages 677-693.
Crossref
Crossref
A. Sverrild, S. Cerps, J. J. Nieto‐Fontarigo, S. Ramu, M. Hvidtfeldt, M. Menzel, J. Kearley, J. M. Griffiths, J. R. Parnes, C. Porsbjerg & L. Uller. (2023) Tezepelumab decreases airway epithelial IL‐33 and T2‐inflammation in response to viral stimulation in patients with asthma. Allergy.
Crossref
Crossref
Jonathan A. Bernstein, Jean-Pierre Llanos, Gillian Hunter, Neil Martin & Christopher S. Ambrose. (2023) Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review. Advances in Therapy.
Crossref
Crossref
Pavel Kolkhir, Cezmi A. Akdis, Mübeccel Akdis, Claus Bachert, Thomas Bieber, Giorgio Walter Canonica, Emma Guttman-Yassky, Martin Metz, Joaquim Mullol, Oscar Palomares, Harald Renz, Sonja Ständer, Torsten Zuberbier & Marcus Maurer. (2023) Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nature Reviews Drug Discovery 22:9, pages 743-767.
Crossref
Crossref
Tomi Kanninen, Li Tao, Roberto Romero, Yi Xu, Marcia Arenas-Hernandez, Jose Galaz, Zhenjie Liu, Derek Miller, Dustyn Levenson, Jonathan M. Greenberg, Jonathan Panzer, Justin Padron, Kevin R. Theis & Nardhy Gomez-Lopez. (2023) Thymic stromal lymphopoietin participates in the host response to intra-amniotic inflammation leading to preterm labor and birth. Human Immunology 84:9, pages 450-463.
Crossref
Crossref
Andrew Menzies-Gow, Arnaud Bourdin, Geoffrey Chupp, Elliot Israel, Åsa Hellqvist, Gillian Hunter, Stephanie L. Roseti, Christopher S. Ambrose, Jean-Pierre Llanos, Bill Cook, Jonathan Corren & Gene Colice. (2023) Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma. Annals of Allergy, Asthma & Immunology 131:3, pages 343-348.e2.
Crossref
Crossref
Austin Heffernan, Amir Shafiee, Teffran Chan, Sydney Sparanese & Andrew Thamboo. (2023) Non‐Type 2 and Mixed Inflammation in Chronic Rhinosinusitis and Lower Airway Disease. The Laryngoscope.
Crossref
Crossref
Marek Lommatzsch, Carl-Peter Criée, Carmen C. M. de Jong, Monika Gappa, Christian Geßner, Michael Gerstlauer, Nina Hämäläinen, Peter Haidl, Eckard Hamelmann, Fritz Horak, Marco Idzko, Atanas Ignatov, Andreas Rembert Koczulla, Stephanie Korn, Michael Köhler, Christiane Lex, Jochen Meister, Katrin Milger-Kneidinger, Dennis Nowak, Monika NothackerOliver Pfaar, Wolfgang Pohl, Alexandra M. Preisser, Klaus F. Rabe, Josef Riedler, Olaf Schmidt, Jens Schreiber, Antje Schuster, Maren Schuhmann, Thomas Spindler, Christian Taube, Johann Christian Virchow, Christian Vogelberg, Claus Franz Vogelmeier, Felix Wantke, Wolfram Windisch, Heinrich Worth, Angela Zacharasiewicz & Roland Buhl. (2023) S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023. Pneumologie 77:08, pages 461-543.
Crossref
Crossref
Sejal Saglani, Laura Yates & Clare M. Lloyd. (2023) Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?. European Journal of Immunology 53:8.
Crossref
Crossref
Christopher S. Ambrose, Elliot IsraelKarin BowenJean-Pierre Llanos, Neil MartinBill CookÅsa HellqvistStephanie Korn, Andrew Menzies-Gow, Stephanie L. RosetiNestor A. Molfino, Janet M. GriffithsJane R. Parnes. (2023) Reply to Lipworth and Chan. American Journal of Respiratory and Critical Care Medicine 208:2, pages 212-213.
Crossref
Crossref
Guy Brusselle & Sebastian Riemann. (2023) Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?. American Journal of Respiratory and Critical Care Medicine 208:1, pages 1-3.
Crossref
Crossref
Jonathan CorrenAndrew Menzies-Gow, Geoffrey ChuppElliot IsraelStephanie KornBill CookChristopher S. Ambrose, Åsa HellqvistStephanie L. Roseti, Nestor A. MolfinoJean-Pierre Llanos, Neil Martin, Karin BowenJanet M. GriffithsJane R. ParnesGene Colice. (2023) Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. American Journal of Respiratory and Critical Care Medicine 208:1, pages 13-24.
Crossref
Crossref
Stephanie Korn, Bill Cook, Lisa J. Simpson, Jean-Pierre Llanos & Christopher S. Ambrose. (2023) Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review. Advances in Therapy 40:7, pages 2944-2964.
Crossref
Crossref
Gabriel Cavalcante Lima Chagas, Débora Xavier, Lorena Gomes, Juliana Ferri-Guerra & Rafael Enrique Hernandez Oquet. (2023) Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis. Current Allergy and Asthma Reports 23:6, pages 287-298.
Crossref
Crossref
Joshua S. Bernstein & Michael E. Wechsler. (2023) Eosinophilic respiratory disorders and the impact of biologics. Current Opinion in Pulmonary Medicine 29:3, pages 202-208.
Crossref
Crossref
Richard Beasley & Anne B Chang. (2023) Is tezepelumab the ubiquitous biologic for severe asthma?. The Lancet Respiratory Medicine 11:5, pages 393-395.
Crossref
Crossref
Andrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, Stephanie Korn, Jonathan Corren, Elliot Israel, Geoffrey Chupp, Artur Bednarczyk, Sandhia Ponnarambil, Scott Caveney, Gun Almqvist, Monika Gołąbek, Linda Simonsson, Kaitlyn Lawson, Karin Bowen, Gene Colice, Jorge Lima Hetzel, Jussara Fiterman, Adelmir Souza Machado, Martti Anton Antila, Marina Andrade Lima, Suzana Erico Tanni Minamoto, Daniela Cavalet Blanco, Patricia Gomes de Matos Bezerra, Pierre-Alain Houle, Catherine Lemiere, Lyle S Melenka, Richard Leigh, Patrick Mitchell, Syed Anees, Bonavuth Pek, Guy Chouinard, Amarjit S Cheema, William Ho-Ching Yang, George Philteos, Pascal Chanez, Arnaud Bourdin, Gilles Devouassoux, Camille Taille, Frédéric De Blay, Christophe Leroyer, Antoine Beurnier, Gilles Garcia, Pierre-Olivier Girodet, François-Xavier Blanc, Antoine Magnan, Stéphanie Wanin, Jocelyne Just, Richard Linde, Stefan Zielen, Karin Förster, Christian Geßner, Margret Jandl, Roland Otto Buhl, Stephanie Korn, Marc Oliver Kornmann, Anneliese Linnhoff, Andrea Ludwig-Sengpiel, Martin Ehlers, Tibor Schmoller, Heiner Steffen, Martin Hoffmann, Joachim Kirschner, Olaf Schmidt, Tobias Welte, Hilke Temme, Ori Wand, Amir Bar-Shai, Gabriel Izbicki, Neville Berkman, Gershon Fink, David Shitrit, Yochai Adir, Piotr Kuna, Barbara Rewerska, Ewa Pisarczyk-Bogacka, Oksana Kurbacheva, Sergey L Mikhailov, Maksim Vasilev, Alexander Emelyanov, Siraj Wali, Amr Albanna, Richard van Zyl-Smit, Ismail Abdullah, Ismail Abdullah, David Bernhardi, Farzana Hoosen, Elvis Irusen, Ismail Kalla, Deepak Lakha, Essack Mitha, Visvakuren Naidoo, Haylene Nell, Trevenesan Padayachee, Jeevren Reddy, Friedrich Petrick, Eugene van der Walt, Zubar Fazal Ahmed Vawda, Hae-Sim Park, Sang Haak Lee, Mi-Kyeong Kim, Jung-Won Park, You Sook Cho, Byung Jae Lee, Yoon-Seok Chang, Choon-Sik Park, Kwan Ho Lee, Sook Young Lee, HyoungKyu Yoon, Kyoung Hee Sohn, Myung Jae Park, Kyung Hoon Min, Young Joo Cho, Han Ki Park, YongChul Lee, Jaechun Lee, Chau-Chyun Sheu, Chih-Yen Tu, Kang-Yun Lee, Sevim Bavbek, Bilun Gemicioglu, Dane Ediger, Ilkay Koca Kalkan, Nataliia Makieieva, Mykola Ostrovskyy, Yevgeniya Dytyatkovs'ka, Yuriy Mykhaylovych Mostovoy, Kyrylo Lebed, Oleh Yakovenko, Atoya Adams, Timothy Mooring, Louis Torres Jr, Marvin Sexton, Ernest Thompson, Jonathan A Bernstein, Paul Lisi, Christopher M Chappel, Jeremy Cole, Gary I Greenwald, Conigliaro Jones, Ryan Mitchell Klein, David N Pham, Selwyn Spangenthal, Steven F Weinstein, Hugh H Windom, Neil L Kao, Mila A Leong, Vinay Mehta, Wendy C Moore, Saligrama Bhat, Bassil Aish, Steven M Meltzer, Jonathan Corren, Mark H Moss, Edward M Kerwin, John Palsted Delgado, Gregg Hudson Lucksinger, Charles A Thompson, Geoffrey Chupp, Sady A Alpizar, Sanjay Virgi Vadgama, Zahid Zafar, Joshua S Jacobs, NJira Lugogo, Neal Jain, Lawrence D Sher, Nabil S Andrawis, David Fuentes, Eric Jason Boren, Erika G Gonzalez, Neetu Talreja, Sheharyar Sandy Durrani, Elliot Israel, Sudhir Sekhsaria, Samuel DeLeon, Mayank Shukla, Martha M Totszollosy Tarpay, Faisal Fakih, Golda Hudes, Jeffrey P Tillinghast, Phillip E Korenblat, Kartik Shenoy, Loretta Que, Shahrukh Ahmad Kureishy, Fred Chukwuemeka Umeh, Vinh Nhu Nguyen, Hanh Thi Chu & Thuy Thi Dieu Nguyen. (2023) Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. The Lancet Respiratory Medicine 11:5, pages 425-438.
Crossref
Crossref
Efthymia Theofani, Aikaterini Tsitsopoulou, Ioannis Morianos & Maria Semitekolou. (2023) Severe Asthmatic Responses: The Impact of TSLP. International Journal of Molecular Sciences 24:8, pages 7581.
Crossref
Crossref
Jonathan Corren, Christopher S. Ambrose, Janet M. Griffiths, Åsa Hellqvist, Andrew W. Lindsley, Jean‐Pierre Llanos, Gene Colice & Andrew Menzies‐Gow. (2022)
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3
NAVIGATOR
study
. Clinical & Experimental Allergy 53:4, pages 417-428.
Crossref
Crossref
Gail M. Gauvreau, Jens M. Hohlfeld, J. Mark FitzGerald, Louis-Philippe Boulet, Donald W. Cockcroft, Beth E. Davis, Stephanie Korn, Oliver Kornmann, Richard Leigh, Irvin Mayers, Henrik Watz, Sarah S. Grant, Monish Jain, Maciej Cabanski, Peter E. Pertel, Ieuan Jones, Jean R. Lecot, Hui Cao & Paul M. O'Byrne. (2023) Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. European Respiratory Journal 61:3, pages 2201193.
Crossref
Crossref
Jonathan Corren, Michael E. Wechsler, Geoffrey Chupp, Stephanie L. Roseti, Åsa Hellqvist, Neil Martin, Jean-Pierre Llanos, Christopher S. Ambrose & Gene Colice. (2023) Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma. The Journal of Allergy and Clinical Immunology: In Practice 11:3, pages 943-945.e2.
Crossref
Crossref
Xuena Yang, Beiting Su, Jing Liu, Li Zheng, Peizhi Tao, Yusen Lin, Xiaoling Zou, Hailing Yang, Wenbin Wu, Ping Meng, Tiantuo Zhang & Hongtao Li. (2023) A CpG-Oligodeoxynucleotide Suppresses Th2/Th17 Inflammation by Inhibiting IL-33/ST2 Signaling in Mice from a Model of Adoptive Dendritic Cell Transfer of Smoke-Induced Asthma. International Journal of Molecular Sciences 24:4, pages 3130.
Crossref
Crossref
Paul M. O'Byrne, Reynold A. PanettieriJr.Jr., Christian Taube, Caterina Brindicci, Margaret Fleming & Pablo Altman. (2023) Development of an inhaled anti-TSLP therapy for asthma. Pulmonary Pharmacology & Therapeutics 78, pages 102184.
Crossref
Crossref
·吾汗 吾丽凡. (2023) Research Progress in the Treatment Methods of Allergic Asthma. Advances in Clinical Medicine 13:07, pages 11050-11055.
Crossref
Crossref
Na Cui, Xuewei Zhu, Chen Zhao, Cuida Meng, Jichao Sha & Dongdong Zhu. (2023) A Decade of Pathogenesis Advances in Non-Type 2 Inflammatory Endotypes in Chronic Rhinosinusitis: 2012–2022. International Archives of Allergy and Immunology 184:12, pages 1237-1253.
Crossref
Crossref
Sara Vázquez‐Mera, Laura Martelo‐Vidal, Pablo Miguéns‐Suárez, Paula Saavedra‐Nieves, Pilar Arias, Coral González‐Fernández, Mar Mosteiro‐Añón, María Dolores Corbacho‐Abelaira, Marina Blanco‐Aparicio, Paula Méndez‐Brea, Francisco Javier Salgado, Juan José Nieto‐Fontarigo & Francisco Javier González‐Barcala. (2022)
Serum exosome
inflamma‐miRs
are surrogate biomarkers for asthma phenotype and severity
. Allergy 78:1, pages 141-155.
Crossref
Crossref
Ilka Jorde, Jens Schreiber & Sabine Stegemann-Koniszewski. (2022) The Role of Staphylococcus aureus and Its Toxins in the Pathogenesis of Allergic Asthma. International Journal of Molecular Sciences 24:1, pages 654.
Crossref
Crossref
Mahmoud Shaban Abdelgalil, Asmaa Ahmed Elrashedy, Ahmed K. Awad, Eman Reda Gad, Mahmoud M. Ali, Ramadan Abdelmoez Farahat, Bassant Hassan Shawki & Mohamed Abd-ElGawad. (2022) Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis. Scientific Reports 12:1.
Crossref
Crossref
Andrew Menzies-Gow, David J. Jackson, Mona Al-Ahmad, Eugene R. Bleecker, Francisco de Borja G. Cosio Piqueras, Stephen Brunton, Giorgio Walter Canonica, Charles K. N. Chan, John Haughney, Steve Holmes, Janwillem Kocks & Tonya Winders. (2022) A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma. Advances in Therapy 39:12, pages 5307-5326.
Crossref
Crossref
Marc Duchesne, Isobel Okoye & Paige Lacy. (2022) Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response. Frontiers in Immunology 13.
Crossref
Crossref
Iain Crossingham, Rebekah Richardson, Timothy SC Hinks, Sally Spencer, Simon Couillard, Anne-Catherine Maynard-Paquette, Doranne Thomassen & Imran Howell. (2022) Biologics for chronic severe asthma: a network meta-analysis. Cochrane Database of Systematic Reviews 2022:10.
Crossref
Crossref
Hugo Farne, Nicholas Glanville, Nicholas Johnson, Tata Kebadze, Julia Aniscenko, Eteri Regis, Jie Zhu, Maria-Belen Trujillo-Torralbo, Onn Min Kon, Patrick Mallia, A Toby Prevost, Michael R Edwards, Sebastian L Johnston, Aran Singanayagam & David J Jackson. (2022) Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial. Thorax 77:10, pages 950-959.
Crossref
Crossref
Arjun Mohan & Njira L. Lugogo. (2022) Phenotyping, Precision Medicine, and Asthma. Seminars in Respiratory and Critical Care Medicine 43:05, pages 739-751.
Crossref
Crossref
M. Gueçamburu & M. Zysman. (2022) BPCO et éosinophiles. Revue des Maladies Respiratoires 39:8, pages 685-697.
Crossref
Crossref
M. Tabardel, E. Clark, P. Demoly & D. Caimmi. (2022) Les anticorps monoclonaux à disposition des allergologues pour traiter l’asthme sévère. Revue Française d'Allergologie 62:6, pages 572-577.
Crossref
Crossref
Si-Zhe Li, Xin-Xing Jin, Yin Shan, Hong-Zhong Jin & Ya-Gang Zuo. (2022) Expression of Thymic Stromal Lymphopoietin in Immune-Related Dermatoses. Mediators of Inflammation 2022, pages 1-9.
Crossref
Crossref
Emmanuel Oshiogwe Okwuofu, Audrey Chee Hui Yong, Jonathan Chee Woei Lim & Johnson Stanslas. (2022) Molecular and immunomodulatory actions of new antiasthmatic agents: Exploring the diversity of biologics in Th2 endotype asthma. Pharmacological Research 181, pages 106280.
Crossref
Crossref
Mathieu Morissette, Krystelle Godbout, Andréanne Côté & Louis-Philippe Boulet. (2022) Asthma COPD overlap: Insights into cellular and molecular mechanisms. Molecular Aspects of Medicine 85, pages 101021.
Crossref
Crossref
Rory Chan, Kirsten Stewart, Rasads Misirovs & Brian J. Lipworth. (2022) Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma. The Journal of Allergy and Clinical Immunology: In Practice 10:6, pages 1497-1505.
Crossref
Crossref
R. Esnaud, W. Trzepizur, C. Chenivesse, G. Devouassoux & C. Taillé. (2022) Biothérapies dans l’asthme : comment s’y retrouver ?. Revue des Maladies Respiratoires Actualités 14:1, pages 1S96-1S99.
Crossref
Crossref
Shogo Sunaga, Junya Tsunoda, Toshiaki Teratani, Yohei Mikami & Takanori Kanai. (2022) Heterogeneity of ILC2s in the Intestine; Homeostasis and Pathology. Frontiers in Immunology 13.
Crossref
Crossref
Chenda Chheang, Stéphane Guinand, Christophe Von Garnier & Claudio Sartori. (2022) New perspectives of biological therapy for severe asthma in adults and adolescents. Swiss Medical Weekly 152:2122, pages w30176.
Crossref
Crossref
Adriana R. Gambardella, Remo Poto, Valentina Tirelli, John T. Schroeder, Gianni Marone, Fabrizio Mattei, Gilda Varricchi & Giovanna Schiavoni. (2022) Differential Effects of Alarmins on Human and Mouse Basophils. Frontiers in Immunology 13.
Crossref
Crossref
Remo Poto, Stefania Loffredo, Francesco Palestra, Gianni Marone, Vincenzo Patella & Gilda Varricchi. (2022) Angiogenesis, Lymphangiogenesis, and Inflammation in Chronic Obstructive Pulmonary Disease (COPD): Few Certainties and Many Outstanding Questions. Cells 11:10, pages 1720.
Crossref
Crossref
Akira Yamasaki, Ryota Okazaki & Tomoya Harada. (2022) Neutrophils and Asthma. Diagnostics 12:5, pages 1175.
Crossref
Crossref
Dennis M Williams. (2022) The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma. Journal of Managed Care & Specialty Pharmacy 28:5, pages 581-583.
Crossref
Crossref
Tara F. Carr & Michael C. Peters. (2022) Novel potential treatable traits in asthma: Where is the research taking us?. Journal of Allergy and Clinical Immunology: Global 1:2, pages 27-36.
Crossref
Crossref
Pier Giorgio Puzzovio, Ron Eliashar & Francesca Levi-Schaffer. (2022) Tezepelumab administration in moderate-to-severe uncontrolled asthma: Is it all about eosinophils?. Journal of Allergy and Clinical Immunology 149:5, pages 1582-1584.
Crossref
Crossref
Danay Maestre‐Batlle, Unni C. Nygaard, Ryan D. Huff, Neil E. Alexis, Scott J. Tebbutt, Stuart E. Turvey, Christopher Carlsten & Anette Kocbach Bølling. (2022) Dibutyl phthalate exposure alters T‐cell subsets in blood from allergen‐sensitized volunteers. Indoor Air 32:4.
Crossref
Crossref
Eun Ju Baek, Hae Un Jung, Tae-Woong Ha, Dong Jun Kim, Ji Eun Lim, Han Kyul Kim, Ji-One Kang & Bermseok Oh. (2022) Genome-Wide Interaction Study of Late-Onset Asthma With Seven Environmental Factors Using a Structured Linear Mixed Model in Europeans. Frontiers in Genetics 13.
Crossref
Crossref
Howraman Meteran, Louise Lindhardt Tønnesen, Pradeesh Sivapalan, Truls Sylvan Ingebrigtsen & Jens-Ulrik Stæhr Jensen. (2022) Recent developments in the management of severe asthma. Breathe 18:1, pages 210178.
Crossref
Crossref
Paolo Luperto, Simonetta Masieri, Carlo Cavaliere, Enrico Compalati, Giorgio Ciprandi & Franco Frati. (2021) Nasal cytology identifies allergic rhinitis phenotypes for managing allergen immunotherapy in clinical practice. Allergo Journal International 31:2, pages 51-55.
Crossref
Crossref
Koichi Ando, Yosuke Fukuda, Akihiko Tanaka & Hironori Sagara. (2022) Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis. Cells 11:5, pages 819.
Crossref
Crossref
Guy G. Brusselle & Gerard H. Koppelman. (2022) Biologic Therapies for Severe Asthma. New England Journal of Medicine 386:2, pages 157-171.
Crossref
Crossref
Beatrice Ragnoli, Jaymin Morjaria, Patrizia Pignatti, Paolo Montuschi, Mariangela Barbieri, Lucrezia Mondini, Luca Ruggero, Liliana Trotta & Mario Malerba. (2022) Dupilumab and tezepelumab in severe refractory asthma: new opportunities. Therapeutic Advances in Chronic Disease 13, pages 204062232210973.
Crossref
Crossref
Lorenzo Salvati, Laura Maggi, Francesco Annunziato & Lorenzo Cosmi. (2021) Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma. Current Opinion in Allergy & Clinical Immunology 21:6, pages 590-596.
Crossref
Crossref
Jonathan Corren, Christopher S. Ambrose, Kinga Sałapa, Stephanie L. Roseti, Janet M. Griffiths, Jane R. Parnes & Gene Colice. (2021) Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy. The Journal of Allergy and Clinical Immunology: In Practice 9:12, pages 4334-4342.e6.
Crossref
Crossref
Tuyet-Hang Pham, Claudia Chen, Gene Colice, Jane R. Parnes, Janet M. Griffiths & Bill Cook. (2021) Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma. Annals of Allergy, Asthma & Immunology 127:6, pages 689-691.
Crossref
Crossref
Sarah Diver, Latifa Khalfaoui, Claire Emson, Sally E Wenzel, Andrew Menzies-Gow, Michael E Wechsler, James Johnston, Nestor Molfino, Jane R Parnes, Ayman Megally, Gene Colice & Christopher E Brightling. (2021) Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine 9:11, pages 1299-1312.
Crossref
Crossref
Corrado Pelaia, Giulia Pelaia, Federico Longhini, Claudia Crimi, Cecilia Calabrese, Luca Gallelli, Angela Sciacqua & Alessandro Vatrella. (2021) Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma. Biomedicines 9:9, pages 1108.
Crossref
Crossref
Chiara Tontini & Silvia Bulfone-Paus. (2021) Novel Approaches in the Inhibition of IgE-Induced Mast Cell Reactivity in Food Allergy. Frontiers in Immunology 12.
Crossref
Crossref
Mariantonia Braile, Alfonso Fiorelli, Daniela Sorriento, Rosa Maria Di Crescenzo, Maria Rosaria Galdiero, Gianni Marone, Mario Santini, Gilda Varricchi & Stefania Loffredo. (2021) Human Lung-Resident Macrophages Express and Are Targets of Thymic Stromal Lymphopoietin in the Tumor Microenvironment. Cells 10:8, pages 2012.
Crossref
Crossref
Andrew Menzies-GowJonathan CorrenArnaud BourdinGeoffrey ChuppElliot IsraelMichael E. WechslerChristopher E. BrightlingJanet M. GriffithsÅsa HellqvistKarin BowenPrimal KaurGun AlmqvistSandhia PonnarambilGene Colice. (2021) Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. New England Journal of Medicine 384:19, pages 1800-1809.
Crossref
Crossref
Yajie Zhang, Daniel A. Davis, Khaled AboulFotouh, Jieliang Wang, Donna Williams, Akhilesh Bhambhani, Michael Zakrewsky, Mohammed Maniruzzaman, Zhengrong Cui & Robert O. WilliamsIIIIII. (2021) Novel formulations and drug delivery systems to administer biological solids. Advanced Drug Delivery Reviews 172, pages 183-210.
Crossref
Crossref
Corrado Pelaia, Giulia Pelaia, Claudia Crimi, Angelantonio Maglio, Luca Gallelli, Rosa Terracciano & Alessandro Vatrella. (2021) Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma. International Journal of Molecular Sciences 22:9, pages 4369.
Crossref
Crossref
Joytri Dutta, Sabita Singh, Archita Ray & Ulaganathan Mabalirajan. 2021. Targeting Cellular Signalling Pathways in Lung Diseases. Targeting Cellular Signalling Pathways in Lung Diseases
97
125
.
Nightingale Syabbalo. (2020) Airway epithelial dysfunction contributes to the pathogenesis of asthma. Journal of Lung, Pulmonary & Respiratory Research 7:4, pages 101-105.
Crossref
Crossref
Claire Emson, Sarah Diver, Latifa Chachi, Ayman Megally, Cherrie Small, John Downie, Jane R. Parnes, Karin Bowen, Gene Colice & Chris E. Brightling. (2020) CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma. Respiratory Research 21:1.
Crossref
Crossref
Enrico Maggi, Irene Veneziani, Lorenzo Moretta, Lorenzo Cosmi & Francesco Annunziato. (2020) Group 2 Innate Lymphoid Cells: A Double-Edged Sword in Cancer?. Cancers 12:11, pages 3452.
Crossref
Crossref
Si-Zhe Li, Xin-Xing Jin, Xiao-Lei Ge, Ya-Gang Zuo & Hong-Zhong Jin. (2020) Thymic Stromal Lymphopoietin Is Implicated in the Pathogenesis of Bullous Pemphigoid by Dendritic Cells. Journal of Immunology Research 2020, pages 1-10.
Crossref
Crossref